Drugs / ispronicline
ispronicline
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT00713765 | Dec 2008 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00777361 | Oct 2008 → Oct 2009 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00689559 | Mar 2008 → Apr 2009 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00686413 | Jan → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00686179 | Jan → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00692510 | Nov 2007 → Sep 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00689637 | Sep 2007 → Feb 2009 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT01466088 | Oct 2011 → May 2014 | Alzheimer disease | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00683462 | May 2008 → Jul 2009 | attention deficit-hyperactivity disorder | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT00528905 | Aug 2007 → Oct 2008 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00501111 | Jul 2007 → Aug 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00109564 | Jan → Oct 2005 | cognitive disorder | Targacept Inc. | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-07-08 | AstraZeneca | AstraZeneca to Advance AZD3480 in ADHD astrazeneca.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ispronicline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00109564 ↗ |
| Known as | AZD3480 | “The objective of this study was to assess the safety, tolerability and efficacy of TC-1734 (AZD3480), a selective α4β2 nicotinic agonist, in the treatment of age-associated...” PMID 20542923 ↗ Jun 2010 |
| Known as | Isproniclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL188462 ↗ |
| Known as | TC-01734 | ChEMBL registry synonym — accepted as the source's own label CHEMBL188462 ↗ |
| Known as | TC-1734 | “This was a within-subjects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (also termed TC-1734) at doses of 5 mg and 50 mg and placebo in...” PMID 23856296 ↗ Jul 2013 |
| Action | Activate | “a selective α4β2 nicotinic agonist” PMID 20542923 ↗ Jun 2010 |
| Modality | Small molecule | — CHEMBL188462 ↗ |
| Route | Oral | “Subjects were randomly assigned to receive orally 25 mg (n = 59), 50 mg (n = 68) TC-1734 (AZD3480) or placebo” PMID 20542923 ↗ Jun 2010 |